Findings suggest a subset of Major Depressive Disorder patients may respond preferentially to vasopressin V1b receptor antagonismMUNICH, Oct. 13, 2025…
EINDHOVEN, the Netherlands, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading…
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer…
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),…
Cognixion's non-invasive brain-computer interface powered by conversational AI, has been honored by TIME Magazine as one of the Best Inventions…
Anathapindika Health’s Signature Nutraceuticals Draw Attention, Impress Buyers at the September Nutraceutical Conference — Just in Time to Gain Momentum…
HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader…
Preclinical data demonstrates that Shape’s engineered AAV5 variant, SHP-DB1, efficiently targets the NHP brain after intravenous injection and transduces >95%…
iBrain™ - Copyright © 2025 NeuroVigil, Inc. All Rights Reserved. iBrain™ prototype iBrain™ with two quarters - Copyright © 2025…
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in…